LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 12, 2024, at 11:00 AM PST. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend this live event. The presentation will fe ...

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference. Mr. Fried and Mrs. Gerber will participate in virtual one-on-one meetings throughout the event on Thursday, February 1, 2024. To arrange a meeting with the ChromaDex mana ...

MirageC/Moment via Getty Images In the volatile arena of healthcare investments, investors are constantly seeking opportunities that not only offer lucrative returns but also align with the developing trends in the sector. One such promising industry that has been gaining traction is the nutraceuticals and supplement industry. As the global population becomes increasingly health-conscious, there is a surge in demand for products that promote well-being. Nutraceuticals and supplements, which include vita ...

Financial Performance - Q3 2023 - ChromaDex's total company net sales increased by 14% year-over-year[11], reaching $195 million[25] - Tru Niagen® net sales increased by 19% year-over-year[11], and accounted for 89% of net sales in Q3 2023, compared to 85% in Q3 2022[26] - Gross margin improved to 614%, up 160 basis points year-over-year, compared to 598%[11] - Adjusted EBITDA was a positive $05 million, a $17 million improvement year-over-year[12] Year-to-Date 2023 - Year-to-date net sales increased by 22% compared to the same period in 2022[38], with Niagen®-related business up 23%[38] - E-commerce net sales reached $379 million, up 11% year-over-year[34] - Watson's & Other B2B net sales reached $140 million, up 42% year-over-year[35] - Niagen® Ingredient net sales reached $78 million, up 78% year-over-year[36] Financial Outlook for 2023 - The company narrowed its full-year 2023 revenue outlook to between 14% - 16% growth[14] - Gross margin is expected to remain stable year-over-year[64] - Selling, Marketing & Advertising expenses are expected to decrease as a percentage of net sales[64] Science and Research - Tru Niagen® 1,000 mg launched in October 2023, which can elevate NAD levels by up to 150% after three weeks[14] - A clinical study published in Cell Reports found that NR supplementation effectively reduced inflammation[13] - Four new human trials on nicotinamide riboside have registered since prior update[67]

Financial Data and Key Metrics - The company ended Q3 2023 with $26.8 million in cash and no debt, reflecting strong fiscal discipline [14] - Total net sales for Q3 2023 were $19.5 million, up 14% year-over-year, with robust gross margins of 61.4% [25] - Adjusted EBITDA for Q3 2023 was positive $0.5 million, a $1.7 million improvement year-over-year [25] - Year-to-date net sales are up 22%, with adjusted EBITDA of $0.7 million and positive operating cash flow of $6.5 million [25] - E-commerce net revenue increased by 13% year-over-year, driven by marketing initiatives [14] - Watson's contributed $3.1 million in Q3 2023, a 19% increase year-over-year [16] - Niagen ingredient sales decreased by 21% year-over-year, partially offset by increased Tru Niagen sales [27] Business Line Performance - E-commerce remains the largest and most consistent revenue source, with a 13% year-over-year growth [14] - Watson's revenue grew 19% year-over-year, driven by the stacking concept of combining Tru Niagen products [16] - The partnership with iHerb has seen 80% of Tru Niagen sales coming from international consumers [17] - Zesty Paws partnership has led to a second order of Niagen, indicating early success in the pet supplement space [18] - Tru Niagen Pro 1000 mg product line launched, offering a clinical strength dose with proven safety and efficacy [19] Market Performance - The company is focusing on optimizing its website and increasing advertising revenues to drive growth [1] - The partnership with Sinopharm in China continues, with Tru Niagen being featured as the best NR supplement in 2023 [36] - The company is exploring opportunities to expand the stacking concept in other markets [16] - The pet supplement market is growing rapidly, with the global market approaching $2 billion [86] Strategic Direction and Industry Competition - The company is investing in R&D and marketing to position itself for accelerated growth in 2024 and beyond [15][53] - ChromaDex is leveraging its scientific foundation and partnerships to maintain its position as a leader in NAD research [20] - The company is defending its intellectual property, with recent patents protecting NR IP for at least the next decade [23] - The partnership with Nestle Health Science has led to the launch of Solgar cellular nutrition products featuring Niagen [38] Management Commentary on Operating Environment and Future Outlook - Management is confident in setting the stage for further growth opportunities in 2024 and beyond [20] - The company expects to achieve close to breakeven adjusted EBITDA for the full year 2023 [53] - Management highlighted the potential of NAD precursors beyond NR, protected by ChromaDex's IP portfolio [24] - The company is optimistic about the partnership with Zesty Paws and future innovations in the pet supplement space [18] Other Important Information - The company announced two published peer-reviewed clinical studies on Parkinson's disease, with a third study recently completed [22] - ChromaDex continues to defend its achievements and inventions, with a favorable court decision against Elysium Health [43] - The company has extended its 10-year collaboration with W.R. Grace to continue delivering high-quality NAD precursors [69] Q&A Session Summary Question: Revenue Guidance and Seasonality - The company expects a sequential uptick in Q4 2023, driven by seasonally higher Niagen ingredient sales and growth from long-term partners [82] - Management anticipates some seasonality in 2024 but sees building blocks for accelerated growth [83] Question: Expansion into the Pet Supplement Market - The company expects the pet supplement market to go beyond canine, with a global market approaching $2 billion [86] - Zesty Paws has already placed a second order, indicating strong initial performance [86] Question: Watson's Store Expansion - Watson's is currently operating in Hong Kong, Singapore, and Taiwan, with potential for expansion within existing stores [64] - The company is optimistic about further growth but notes that Watson's operates as independently managed businesses [64] Question: Tru Niagen Pro Product Rollout - The Tru Niagen Pro 1000 mg product is targeted at consumers looking to take aging into their own hands, with professional athletes and teams already using it [66][100] - The product has been certified for Sport by NSF International, and the company is leading with MLB and NHL [92] Question: Website Performance and Growth Expectations - The company is seeing improvements in key performance indicators for its website, with a high conversion rate but a need for increased traffic [103] - Management expects significant growth in website sales by Q1 2024 [103] Question: E-commerce Growth and Efficiency - E-commerce growth remains strong, with Amazon performing well, while the website is taking longer to turn around [59] - The company is focusing on scaling its website spend while maintaining targeted efficiencies [52]

Table of Contents General Risks: We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise suf icient capital on favorable terms or at all. Table of Contents Global, market and economic conditions may negatively impact our business, financial condition and share price. As a consumer-focused company, we expect to generate a significant percentage of our future revenue from sales of our Tru Niagen® product. As a result, th ...

ChromaDex Corporation (NASDAQ:CDXC) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Brianna Gerber - Chief Financial Officer Conference Call Participants Ram Selvaraju - H.C. Wainwright Jeff Van Sinderen - B. Riley Mitch Pinheiro - Sturdivant Sean McGowan - ROTH MKM Operator Hello. My name is Aisha and I'll be your conference operator today. At this time, I'd like to welcome everyone to the ChromaD ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|---------------------------------------------------------------------------------------| | Delaware | | 26-2940963 | | (State or other jurisdiction of | | (I.R.S. Employer | | incorporation or organization) | | Identification No.) | | 10900 Wilshire Blvd. Suite 600, Los Angeles, | Califor ...

ChromaDex Corporation (NASDAQ:CDXC) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Brianna Gerber - Chief Financial Officer Andrew Shao - Senior Vice President-Scientific and Regulatory Affairs Conference Call Participants Jeff Van Sinderen - B. Riley Ram Selvaraju - H.C. Wainwright Mitch Pinheiro - Sturdivant Sean McGowan - ROTH MKM JP Mark - Farmhouse Equity Research Jeff Cohen - Ladenburg Thalmann ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|-------|---------------------|-------|---------------------------|------------------------------------------------|-------|---------------------------|-------| | (In thousands except per share data and remaining contractual term) | | Number of Options | | Weighted \nExercise Price | Average \nRemaining Contractual Term (Years) | | Aggregate Intrinsic Value | | | Outs ...